IRIS
DEL MASTRO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 27.318
AS - Asia 86
SA - Sud America 41
NA - Nord America 4
Totale 27.449
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 27.309
CN - Cina 50
BR - Brasile 34
SG - Singapore 26
NL - Olanda 6
VN - Vietnam 6
AR - Argentina 4
US - Stati Uniti d'America 4
HK - Hong Kong 2
PY - Paraguay 2
BD - Bangladesh 1
BY - Bielorussia 1
CO - Colombia 1
ES - Italia 1
FI - Finlandia 1
ID - Indonesia 1
Totale 27.449
Salva come PNG Salva come JPEG
Città #
Genova 12.582
Genoa 9.856
Rapallo 2.503
Vado Ligure 2.270
Bordighera 95
Beijing 25
Singapore 20
Amsterdam 6
São Paulo 6
Ashburn 4
Curitiba 4
Ho Chi Minh City 3
Teolo 3
Hong Kong 2
Alfenas 1
Araçatuba 1
Barcelona 1
Bauru 1
Bekasi 1
Biên Hòa 1
Buenos Aires 1
Buritis 1
Campos dos Goytacazes 1
Ciudad del Este 1
Ezeiza 1
Fighiera 1
Gravataí 1
Guanambi 1
Guaíba 1
Hải Dương 1
Irupi 1
Lappeenranta 1
Lấp Vò 1
Maceió 1
Minsk 1
Nova Iguaçu 1
Ortigueira 1
Paulo Afonso 1
Piraquara 1
Rio Bonito 1
Rio do Sul 1
San Alberto 1
Santa Bárbara d'Oeste 1
Santa Marta 1
Sousa 1
São Francisco do Sul 1
São João del Rei 1
Vargem Grande Paulista 1
Votorantim 1
Várzea Paulista 1
Águas Lindas de Goiás 1
Totale 27.416
Salva come PNG Salva come JPEG
Nome #
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 213
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 201
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 197
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. 193
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 193
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 173
Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients 172
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 168
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 166
Cancer and fertility preservation: international recommendations from an expert meeting 166
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 165
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 164
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 162
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 160
Management of young women with early breast cancer 156
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial 156
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 153
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 152
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 152
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 151
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 148
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 147
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 144
Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes 143
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 143
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 143
Targeting bone metastatic cancer: Role of the mTOR pathway 142
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 141
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. 141
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer 141
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 140
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 140
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 140
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 139
News on the medical treatment of young women with early-stage HER2-negative breast cancer 139
Predicting mood disorders in breast cancer patients. 138
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 138
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 138
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 137
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations 137
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 137
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 136
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 136
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology 136
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer 136
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 136
A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes 135
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity 134
Treatment with aromatase inhibitors and markers of cardiovascular disease 132
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 132
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole 132
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 131
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 131
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 131
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. 131
Anthracycline-free therapy for HER2-amplified breast cancer 129
A case where switching end points for clinical trial interpretation might be the right choice 129
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 129
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study 128
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 127
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 127
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study 127
Fertility, sexuality and cancer in young adult women 127
Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence 126
Letrozole withdrawal response in locally advanced breast cancer 124
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial 123
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 123
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 123
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al. 123
Reply to the letter "Safety of fertility preservation in women with breast cancer" 123
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group 122
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 122
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 122
Taxane-containing chemotherapy in the treatment of early breast cancer patients 121
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 121
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 121
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 121
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 121
Optimization of a wga-free molecular tagging-based ngs protocol for ctcs mutational profiling 120
Randomized cooperative study of perioperative chemotherapy in breast cancer. 119
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives 119
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 118
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors 117
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases 117
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project 117
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 117
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 117
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis 116
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 115
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going 114
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 114
Long-term follow-up of The Intergroup Exemestane Study 113
Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer 112
Safety of adjuvant aromatase inhibitor therapy 112
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors 112
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications 111
Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy. 110
Medical approaches to preservation of fertility in female cancer patients 108
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 108
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer 107
Totale 13.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.881
article - articoli 109.673
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 208
Totale 219.762
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.623 0 0 0 224 117 195 136 234 111 287 143 176
2021/20222.704 142 108 128 261 73 302 97 616 279 247 96 355
2022/20233.079 274 249 31 283 448 457 79 379 507 27 305 40
2023/20241.831 72 227 55 250 145 191 127 154 80 106 110 314
2024/20255.998 194 442 159 382 725 711 494 956 295 340 594 706
2025/20264.363 1.232 517 1.623 991 0 0 0 0 0 0 0 0
Totale 28.581